Previous 10 | Next 10 |
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 2.3% to $11.595 on volume of 119,263,238 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.8% to $4.3323 on volume of 111,414,526 shares SoundHound AI Inc. (SOUN) rose 0.0% to $3.7601 on volu...
2024-02-16 07:30:02 ET Needham analyst issues MARKET OUTPERFORM recommendation for ATRC on February 16, 2024 07:00AM ET. The previous analyst recommendation was Market Outperform. ATRC was trading at $34.21 at issue of the analyst recommendation. The overall analyst cons...
2024-02-15 22:30:04 ET AtriCure, Inc. (ATRC) Q4 2023 Earnings Conference Call February 15, 2024, 16:30 PM ET Company Participants Marissa Bych - Gilmartin Group, Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Finan...
2024-02-15 16:07:24 ET More on AtriCure AtriCure Q4 2023 Earnings Preview AtriCure stock jumps on upbeat 2024 revenue outlook Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure ...
Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year ...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-01-27 20:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results ...
2024-01-16 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 12:01:16 ET More on AtriCure AtriCure: Appeal Lures For This Cure AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript AtriCure defended at UBS despite Medtronic’s rival product Needham says Medtronic could create overhang on AtriCure shar...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Bank of America Securi...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE ® + cryoablation probe, leve...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, M...